Mega Genomics Limited (HKG:6667)
Hong Kong · Delayed Price · Currency is HKD 7.19
+0.02 (0.28%)
Sep 11, 2026, 3:51 PM HKT
Mega Genomics Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,608 | 1,615 | 2,505 | 2,449 | 3,110 | - | |
Market Cap Growth | -0.43% | -35.53% | 2.28% | -21.25% | - | - |
Enterprise Value | 1,151 | 1,113 | 2,003 | 1,995 | 2,686 | - |
Last Close Price | 7.17 | 7.03 | 10.72 | 10.05 | 12.69 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 50.03 | 53.71 | 52.26 | 74.01 | - | - |
Forward PE | - | 9.77 | 9.77 | 9.77 | 14.29 | - |
PS Ratio | 3.89 | 5.87 | 14.33 | 14.69 | 18.88 | - |
PB Ratio | 2.30 | 2.38 | 3.83 | 3.45 | 4.45 | - |
P/TBV Ratio | 2.31 | 2.38 | 3.83 | 3.45 | 4.46 | - |
P/FCF Ratio | - | - | 41.74 | 17.39 | - | - |
P/OCF Ratio | - | - | 41.19 | 13.58 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.78 | 4.05 | 11.46 | 11.97 | 16.31 | - |
EV/EBITDA Ratio | 28.21 | 27.93 | 32.88 | 51.79 | - | - |
EV/EBIT Ratio | 38.21 | 37.63 | 39.11 | 67.80 | - | - |
EV/FCF Ratio | - | - | 33.37 | 14.17 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.05 | 0.06 | 0.08 | 0.02 | 0.02 |
Debt / EBITDA Ratio | 0.81 | 0.70 | 0.55 | 1.17 | - | 0.09 |
Debt / FCF Ratio | - | - | 0.61 | 0.38 | - | 0.44 |
Net Debt / Equity Ratio | -0.65 | -0.67 | -0.75 | -0.74 | -0.64 | -0.65 |
Net Debt / EBITDA Ratio | -11.21 | -11.42 | -8.01 | -13.66 | 24.73 | -3.85 |
Net Debt / FCF Ratio | - | 24.52 | -8.13 | -3.74 | 33.36 | -17.04 |
Asset Turnover | 0.47 | 0.32 | 0.21 | 0.20 | 0.20 | 0.39 |
Inventory Turnover | 12.90 | 5.89 | 9.95 | 15.92 | 18.85 | 22.54 |
Quick Ratio | 3.26 | 3.31 | 6.43 | 5.85 | 7.37 | 9.55 |
Current Ratio | 3.56 | 3.64 | 6.90 | 6.09 | 7.62 | 9.82 |
Return on Equity (ROE) | 4.03% | 4.41% | 7.15% | 4.76% | -2.69% | 18.15% |
Return on Assets (ROA) | 2.15% | 2.11% | 3.92% | 2.22% | -2.06% | 11.08% |
Return on Invested Capital (ROIC) | 9.96% | 12.22% | 25.02% | 11.45% | -10.52% | 78.45% |
Return on Capital Employed (ROCE) | 4.20% | 4.20% | 7.40% | 3.90% | -3.90% | 15.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.76% | 1.86% | 1.91% | 1.35% | -0.64% | - |
FCF Yield | - | -1.15% | 2.40% | 5.75% | -0.43% | - |
Dividend Yield | 2.47% | 2.38% | - | - | - | - |
Buyback Yield / Dilution | 3.60% | 4.81% | 2.05% | -2.65% | -62.09% | - |
Total Shareholder Return | 6.06% | 7.18% | 2.05% | -2.65% | -62.09% | - |